Literature DB >> 22207924

Serum HIF-1alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer.

Zhong-zhi Jia1, Guo-min Jiang, Yao-liang Feng.   

Abstract

OBJECTIVE: To investigate the expression levels of serum hypoxia inducible factor 1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) pre- and post-transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC), and correlations between prognosis factors and serum HIF-1alpha as well asVEGF levels.
METHODS: Forty consecutive patients fulfilling diagnostic criteria for PLC undergoing TACE from March 2008 to May 2009 were enrolled into the study. The serum HIF-1alpha and VEGF levels of PLC patients pre- and 1 day, 1 week, 1 month post-TACE were analyzed using ELISA, and compared with that of 20 healthy volunteers. Patients were divided into complete response (CR) and partial response (PR), stable disease (SD), progressive disease (PD) groups according to the therapeutic efficacy. Pearson correlation was used to analyze the correlation between different clinical variables and serum HIF- 1alpha and VEGF levels before TACE, and correlation between serum HIF-1alpha and VEGF levels was also evaluated.
RESULTS: The expression levels of serum HIF-1alpha and VEGF in PLC patients were 154.94 +/- 83.29 and 264.00 +/- 148.10 pg/mL pre-TACE, and both of them were significantly higher than those in control group (23.84 +/- 8.15 and 69.78 +/- 21.42 pg/mL, all P<0.01). One day after TACE, both serum HIF-1alpha (570.64 +/- 230.87 pg/mL) and VEGF levels (362.07 +/- 102.25 pg/mL) reached the peak values (all P<0.01). One week post-TACE, expression levels of them were decreased (198.62 +/- 92.11 and 283.52 +/- 145.46 pg/mL respectively), but still significantly higher than those before TACE (all P<0.01). The levels of both HIF-1alpha (133.96 +/- 57.02 vs. 255.74 +/- 123.44 pg/mL) and VEGF (150.96 +/- 84.89 vs. 368.95 +/- 161.90 pg/mL) in CR group 1 month post-TACE were significantly lower than those in PR+SD+PD group (all P<0.01). The level of serum HIF-1alpha was positively correlated with serum VEGF level (r=0.42, P<0.001). Both serum HIF-1alpha and VEGF levels were observed to be correlated with portal vein tumor thrombi (P<0.05) and metastasis (P<0.05).
CONCLUSION: The HIF- 1alpha and VEGF might play an important role in relapse of PLC. They might be considered as predictors of the efficacy ofTACE and metastasis of PLC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22207924     DOI: 10.1016/s1001-9294(11)60041-2

Source DB:  PubMed          Journal:  Chin Med Sci J        ISSN: 1001-9294


  24 in total

1.  Development and Validation of Sorafenib-eluting Microspheres to Enhance Therapeutic Efficacy of Transcatheter Arterial Chemoembolization in a Rat Model of Hepatocellular Carcinoma.

Authors:  Wooram Park; Soojeong Cho; Jingran Ji; Robert J Lewandowski; Andrew C Larson; Dong-Hyun Kim
Journal:  Radiol Imaging Cancer       Date:  2021-01-08

2.  The effect of transcatheter arterial chemoembolization on hepatitis C viremia.

Authors:  Parag Mahale; Ahmed Kaseb; Marta Davila; Harrys A Torres
Journal:  Oncologist       Date:  2012

3.  Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.

Authors:  Isabel Theresa Schobert; Lynn Jeanette Savic; Julius Chapiro; Khaled Bousabarah; Evan Chen; Fabian Laage-Gaupp; Jonathan Tefera; Nariman Nezami; MingDe Lin; Jeffrey Pollak; Todd Schlachter
Journal:  Eur Radiol       Date:  2020-05-19       Impact factor: 5.315

Review 4.  Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights.

Authors:  Maria Tampaki; Polyxeni P Doumba; Melanie Deutsch; John Koskinas
Journal:  World J Hepatol       Date:  2015-07-18

5.  Impact of pathological response after preoperative transcatheter arterial chemoembolization (TACE) on incidences of microvascular invasion and early tumor recurrence in hepatocellular carcinoma: a multicenter propensity score matching analysis.

Authors:  Yun Yang; Zheng Dang; Peng Lu; Youwen Qian; Kongying Lin; Zeya Pan; Wan Yee Lau; Weiping Zhou
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

6.  Expression of cluster of differentiation 151 prior to and following transcatheter arterial chemoembolization therapy in patients with hepatocellular carcinoma and its association with clinicopathological characteristics.

Authors:  Zhen Kang; Enhua Xiao
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

Review 7.  Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis.

Authors:  Jia-Yan Ni; Lin-Feng Xu; Wei-Dong Wang; Hong-Liang Sun; Yao-Ting Chen
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma.

Authors:  John Lammli; Minyan Fan; Howard G Rosenthal; Meghan Patni; Elizabeth Rinehart; Gerardo Vergara; Elizabeth Ablah; Paul H Wooley; George Lucas; Shang-You Yang
Journal:  Int Orthop       Date:  2012-08-02       Impact factor: 3.075

9.  The relationship between the preoperative plasma level of HIF-1α and clinic pathological features, prognosis in non-small cell lung cancer.

Authors:  Jiabei He; Ying Hu; Mingming Hu; Siyi Zhang; Baolan Li
Journal:  Sci Rep       Date:  2016-02-08       Impact factor: 4.379

10.  Liposomal curcumin inhibits hypoxia-induced angiogenesis after transcatheter arterial embolization in VX2 rabbit liver tumors.

Authors:  Feng Dai; Xiuming Zhang; Wenrong Shen; Jun Chen; Liucheng Liu; Gejun Gao
Journal:  Onco Targets Ther       Date:  2015-09-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.